Cited by 280Pancreatic and Hepatic Oncology ResearchCancer Genomics and DiagnosticsPancreatitis Pathology and Treatment

The DOI matches its Crossref record; 37 of the 43 references it cites were found in a registry or an index.

Clinical Significance of the Genetic Landscape of Pancreatic Cancer and Implications for Identification of Potential Long-term Survivors

Open access

Yachida, Shinichi, White, Catherine M., Naito, Yoshiki, Zhong, Yi, Brosnan, Jacqueline A., Macgregor-Das, Anne M., Morgan, Richard A., Saunders, Tyler, Laheru, Daniel A., Herman, Joseph M., Hruban, Ralph H., Klein, Alison P., Jones, Siân, Velculescu, Victor, Wolfgang, Christopher L., Iacobuzio-Donahue, Christine A.·2012·Clinical Cancer Research

DOI 10.1158/1078-0432.ccr-12-1215PMC PMC3500447

Published version of a preprint

Open this paper in CoChat — free account

Abstract

Purpose: Genetic alterations of KRAS, CDKN2A, TP53, and SMAD4 are the most frequent events in pancreatic cancer. We determined the extent to which these 4 alterations are coexistent in the same carcinoma, and their impact on patient outcome. Experimental Design: Pancreatic cancer patients who underwent an autopsy were studied (n = 79). Matched primary and metastasis tissues were evaluated for intragenic mutations in KRAS, CDKN2A, and TP53 and immunolabeled for CDKN2A, TP53, and SMAD4 protein products. The number of altered driver genes in each carcinoma was correlated to clinicopathologic features. Kaplan–Meier estimates were used to determine median disease free and overall survival, and a Cox proportional hazards model used to compare risk factors. Results: The number of genetically altered driver genes in a carcinoma was variable, with only 29 patients (37%) having an alteration in all 4 genes analyzed. The number of altered driver genes was significantly correlated with disease free survival (P = 0.008), overall survival (P = 0.041), and metastatic burden at autopsy (P = 0.002). On multivariate analysis, the number of driver gene alterations in a pancreatic carcinoma remained independently associated with overall survival (P = 0.046). Carcinomas with only 1 to 2 driver alterations were enriched for those patients with the longest survival (median 23 months, range 1 to 53). Conclusions: Determinations of the status of the 4 major driver genes in pancreatic cancer, and specifically the extent to which they are coexistent in an individual patients cancer, provides distinct information regarding disease progression and survival that is independent of clinical stage and treatment status. Clin Cancer Res; 18(22); 6339–47. ©2012 AACR.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-12-1215

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cancer statistics, 2012
Siegel, R., Naishadham, D., & Jemal, A. (2012) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20138 · Cited by 10,679
Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses
Jones, S., Zhang, X., Parsons, D. W., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Kamiyama, H., Jimeno, A., et al. (2008) · Science · doi:10.1126/science.1164368 · Cited by 3,969
Self-citation
Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice
Hingorani, S. R., Wang, L., Multani, A. S., Combs, C., Deramaudt, T. B., Hruban, R. H., Rustgi, A. K., Chang, S., & Tuveson, D. A. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.04.023 · Cited by 2,609
Self-citation
Distant metastasis occurs late during the genetic evolution of pancreatic cancer
Yachida, S., Jones, S., Bozic, I., Antal, T., Leary, R., Fu, B., Kamiyama, M., Hruban, R. H., Eshleman, J. R., Nowak, M. A., et al. (2010) · Nature · doi:10.1038/nature09515 · Cited by 2,502
Self-citation
Massive genomic rearrangement acquired in a single catastrophic event during cancer development
Stephens, P. J., Greenman, C. D., Fu, B., Yang, F., Bignell, G. R., Mudie, L. J., Pleasance, E. D., Lau, K. W., Beare, D., Stebbings, L. A., et al. (2011) · Cell · doi:10.1016/j.cell.2010.11.055 · Cited by 2,414
Self-citation
Hyperactive Ras in developmental disorders and cancer
Schubbert, S., Shannon, K., & Bollag, G. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2109 · Cited by 1,583
The patterns and dynamics of genomic instability in metastatic pancreatic cancer
Campbell, P. J., Yachida, S., Mudie, L. J., Stephens, P. J., Pleasance, E. D., Stebbings, L. A., Morsberger, L. A., Latimer, C., McLaren, S., Lin, M.-L., et al. (2010) · Nature · doi:10.1038/nature09460 · Cited by 1,317
Self-citation
Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma
Caldas, C., Hahn, S. A., da Costa, L. T., Redston, M. S., Schutte, M. E. M., Seymour, A. B., Weinstein, C. L., Hruban, R. H., Yeo, C. J., & Kern, S. E. (1994) · Nature Genetics · doi:10.1038/ng0994-27 · Cited by 1,132
Self-citation
DPC4 Gene Status of the Primary Carcinoma Correlates With Patterns of Failure in Patients With Pancreatic Cancer
Iacobuzio-Donahue, C. A., Fu, B., Yachida, S., Luo, M., Abe, H., Henderson, C. M., Vilardell, F., Wang, Z., Keller, J. W., Banerjee, P., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.7188 · Cited by 1,081
Self-citation
Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma
Aguirre, A. J., Bardeesy, N., Sinha, M., Lopez, L., Tuveson, D. A., Horner, J., Redston, M. S., & DePinho, R. A. (2003) · Genes & Development · doi:10.1101/gad.1158703 · Cited by 1,033 · cited 4×
“Furthermore, although genetically engineeredmousemodels indicate that the concomitant expression of thesemutated genes is crucial to progress to invasion and metastasis in PDACs (15–19), the extent to which the coexistence of 3 or more of these altered genes in the same PDAC influence thebiologic behavior and survival…”
BackgroundInfluential

Show all 43 references

Sorted by citations

Items 101–200 of 280

Is there a CDKN2A-centric network in pancreatic ductal adenocarcinoma?
Wu, C. L., Yang, P., Liu, B., & Tang, Y. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s232464 · Cited by 29
Expanding the Spectrum of Pancreatic Cancers Responsive to Vesicular Stomatitis Virus-Based Oncolytic Virotherapy: Challenges and Solutions
Holbrook, M. C., Goad, D. W., & Grdzelishvili, V. Z. (2021) · Cancers · doi:10.3390/cancers13051171 · Cited by 26
Expression and role of the immune checkpoint regulator PD-L1 in the tumor-stroma interplay of pancreatic ductal adenocarcinoma
Daunke, T., Beckinger, S., Rahn, S., Krüger, S., Heckl, S. M., Schäfer, H., Wesch, D., Pilarsky, C. P., Eckstein, M., Hartmann, A., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1157397 · Cited by 24
Invasion and metastasis—recent advances and future challenges
Chambers, A. F., & Werb, Z. (2015) · Journal of Molecular Medicine · doi:10.1007/s00109-015-1269-z · Cited by 23
Pancreatic cancer genomics: insights and opportunities for clinical translation
Makohon-Moore, A. P., Brosnan‐Cashman, J. A., & Iacobuzio–Donahue, C. A. (2013) · Genome Medicine · doi:10.1186/gm430 · Cited by 25
Self-citation
Clinical outcome and expression of mutant P53, P16, and Smad4 in lung adenocarcinoma: a prospective study
Bian, C., Li, Z., Xu, Y., Wang, J., Xu, L., & Shen, H. (2015) · World Journal of Surgical Oncology · doi:10.1186/s12957-015-0502-0 · Cited by 25
Targeted therapies of solid cancers
Awada, A. H., & Aftimos, P. G. (2013) · Current Opinion in Oncology · doi:10.1097/cco.0b013e32835ff318 · Cited by 23
Post‐operative mortality and recurrence patterns in pancreatic cancer according to KRAS mutation and CDKN2A , p53, and SMAD4 expression
Masugi, Y., Takamatsu, M., Tanaka, M., Hara, K., Inoue, Y., Hamada, T., Suzuki, T., Arita, J., Hirose, Y., Kawaguchi, Y., et al. (2023) · The Journal of Pathology: Clinical Research · doi:10.1002/cjp2.323 · Cited by 23
Characterization of pancreatic ductal adenocarcinoma using whole transcriptome sequencing and copy number analysis by single-nucleotide polymorphism array
Marco, M. D., Astolfi, A., Grassi, E., Vecchiarelli, S., Macchini, M., Indio, V., Casadei, R., Ricci, C., D’Ambra, M., Taffurelli, G., et al. (2015) · Molecular Medicine Reports · doi:10.3892/mmr.2015.4344 · Cited by 23
Multiparametric Modelling of Survival in Pancreatic Ductal Adenocarcinoma Using Clinical, Histomorphological, Genetic and Image-Derived Parameters
Kaissis, G. A., Jungmann, F., Ziegelmayer, S., Lohöfer, F. K., Harder, F. N., Schlitter, A. M., Muckenhuber, A., Steiger, K., Schirren, R., Frieß, H., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9051250 · Cited by 22
Epigenetics in Pancreatic Ductal Adenocarcinoma: Impact on Biology and Utilization in Diagnostics and Treatment
Elrakaybi, A., Ruess, D. A., Lübbert, M., Quante, M., & Becker, H. (2022) · Cancers · doi:10.3390/cancers14235926 · Cited by 22
Genomic Landscapes of Pancreatic Neoplasia
Wood, L. D., & Hruban, R. H. (2015) · Journal of Pathology and Translational Medicine · doi:10.4132/jptm.2014.12.26 · Cited by 22
Self-citation
Clinical Significance of Serum p53 Antibody in the Early Detection and Poor Prognosis of Gastric Cancer
Kunizaki, M., Fukuda, A., Wakata, K., Tominaga, T., Nonaka, T., Miyazaki, T., Matsumoto, K., Sumida, Y., Hidaka, S., Yasutake, T., et al. (2017) · Anticancer Research · doi:10.21873/anticanres.11540 · Cited by 21
A New Strategy to Control and Eradicate “Undruggable” Oncogenic K-RAS-Driven Pancreatic Cancer: Molecular Insights and Core Principles Learned from Developmental and Evolutionary Biology
Sciver, R. E. V., Lee, M., Lee, C. G. L., Lafever, A., Svyatova, E. A., Kanda, K., Collier, A. L., van Reesema, L. L. S., Tang-Tan, A. M., Zheleva, V. P., et al. (2018) · Cancers · doi:10.3390/cancers10050142 · Cited by 21
Comprehensive Analysis of Somatic Mutations in Driver Genes of Resected Pancreatic Ductal Adenocarcinoma Reveals KRAS G12D and Mutant TP53 Combination as an Independent Predictor of Clinical Outcome
Shoucair, S., Habib, J. R., Pu, N., Kinny‐Köster, B., van Oosten, A. F., Javed, A. A., Lafaro, K. J., He, J. P., Wolfgang, C. L., & Yu, J. (2021) · Annals of Surgical Oncology · doi:10.1245/s10434-021-11081-z · Cited by 20
Self-citation
The role of microRNAs in the modulation of cancer-associated fibroblasts activity during pancreatic cancer pathogenesis
Barrera, L. N., Ridley, P., Bermejo‐Rodríguez, C., Costello, E., & Pérez-Mancera, P. A. (2022) · Journal of Physiology and Biochemistry · doi:10.1007/s13105-022-00899-0 · Cited by 22
Low Frequency of KRAS Mutation in Pancreatic Ductal Adenocarcinomas in Korean Patients and Its Prognostic Value
Kwon, M. J., Jeon, J. Y., Park, H., Nam, E. S., Cho, S. J., Shin, H. S., Kwon, J. H., Kim, J. S., Han, B., Kim, D. H., et al. (2014) · Pancreas · doi:10.1097/mpa.0000000000000280 · Cited by 22
PEPT1 is essential for the growth of pancreatic cancer cells: a viable drug target
Schniers, B. K., Rajasekaran, D., Korać, K., Sniegowski, T., Ganapathy, V., & Bhutia, Y. D. (2021) · Biochemical Journal · doi:10.1042/bcj20210377 · Cited by 21
Phenotypic heterogeneity and tumor immune microenvironment directed therapeutic strategies in pancreatic ductal adenocarcinoma
Ramesh, R. P. G., Yasmin, H., Ponnachan, P., al-Ramadi, B. K., Kishore, U., & Joseph, A. M. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1573522 · Cited by 22
Two Novel Nomograms Predicting the Risk and Prognosis of Pancreatic Cancer Patients With Lung Metastases: A Population-Based Study
Zhang, W., Ji, L., Zhong, X., Zhu, S., Zhang, Y., Ge, M., Kang, Y., & Bi, Q. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.884349 · Cited by 20
Pirfenidone-loaded exosomes derived from pancreatic ductal adenocarcinoma cells alleviate fibrosis of premetastatic niches to inhibit liver metastasis
Zhao, J., Zhu, Y., Li, Z., Liang, J., Zhang, Y., Zhou, S., Zhang, Y., Fan, Z., Shen, Y., Liu, Y., et al. (2022) · Biomaterials Science · doi:10.1039/d2bm00770c · Cited by 20
Circulating tumor DNA in molecular assessment feasibly predicts early progression of pancreatic cancer that cannot be identified via initial imaging
Watanabe, F., Suzuki, K., Aizawa, H., Endo, Y., Takayama, Y., Kakizawa, N., Kato, T., Noda, H., & Rikiyama, T. (2023) · Scientific Reports · doi:10.1038/s41598-023-31051-7 · Cited by 20
Epigenetic control of pancreatic cancer metastasis
Krauß, L., Schneider, C., Heßmann, E., Saur, D., & Schneider, G. (2023) · Cancer and Metastasis Reviews · doi:10.1007/s10555-023-10132-z · Cited by 20
An Inflammatory Response Related Gene Signature Associated with Survival Outcome and Gemcitabine Response in Patients with Pancreatic Ductal Adenocarcinoma
Xiao, Z., Jin-yin, L., Yu, Q., Zhou, T., Duan, J., Yang, Z., Liu, C., & Xu, F. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.778294 · Cited by 20
SMAD4 and KRAS Status Shapes Cancer Cell–Stromal Cross-Talk and Therapeutic Response in Pancreatic Cancer
Lloyd, E. G., Jihad, M., Manansala, J. S., Li, W., Cheng, P. S. W., Teles, S. P., Mucciolo, G., Henríquez, J. A., Ashworth, S., Luo, W., et al. (2025) · Cancer Research · doi:10.1158/0008-5472.can-24-2330 · Cited by 18
Surgical margin clearance and extended chemotherapy defines survival for synchronous oligometastatic liver lesions of the ductal adenocarcinoma of the pancreas
Safi, S. A., Fluegen, G., Rehders, A., Häberle, L., Fung, S., Keitel, V., Krieg, A. H., Knoefel, W. T., & Lehwald, N. (2021) · International Journal of Clinical Oncology · doi:10.1007/s10147-021-01961-5 · Cited by 18
The identification of liver metastasis- and prognosis-associated genes in pancreatic ductal adenocarcinoma
Luan, H., He, Y., Zhang, T., Su, Y., & Zhou, L. (2022) · BMC Cancer · doi:10.1186/s12885-022-09577-2 · Cited by 18
Insights into the metastatic cascade through research autopsies
Hessey, S., Fessas, P., Zaccaria, S., Jamal‐Hanjani, M., & Swanton, C. (2023) · Trends in cancer · doi:10.1016/j.trecan.2023.03.002 · Cited by 19
Statin Exposure and Pancreatic Cancer Incidence: A Japanese Regional Population-Based Cohort Study, the Shizuoka Study
Saito, K., Sato, Y., Nakatani, E., Kaneda, H., Yamamoto, S., Miyachi, Y., & Itoh, H. (2021) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-21-0123 · Cited by 19
Isolated Pancreatic Metastases of Renal Cell Cancer: Genetics and Epigenetics of an Unusual Tumour Entity
Sellner, F., Thalhammer, S., & Klimpfinger, M. (2022) · Cancers · doi:10.3390/cancers14061539 · Cited by 17
Loss of tumor suppressor WWOX accelerates pancreatic cancer development through promotion of TGFβ/BMP2 signaling
Husanie, H., Abu‐Remaileh, M., Maroun, K., Abu-Tair, L., Safadi, H., Atlan, K., Golan, T., & Aqeilan, R. I. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-05519-9 · Cited by 17
Genetic variants in the liver kinase B1‐AMP‐activated protein kinase pathway genes and pancreatic cancer risk
Xu, X., Qian, D., Liu, H., Cruz, D., Luo, S., Walsh, K. M., Abbruzzese, J. L., Zhang, X., & Wei, Q. (2019) · Molecular Carcinogenesis · doi:10.1002/mc.23018 · Cited by 16
Current Pathology Model of Pancreatic Cancer
Szymoński, K., Milian-Ciesielska, K., Lipiec, E. W., & Adamek, D. (2022) · Cancers · doi:10.3390/cancers14092321 · Cited by 15
The germline/somatic DNA damage repair gene mutations modulate the therapeutic response in Chinese patients with advanced pancreatic ductal adenocarcinoma
Shui, L., Li, X., Peng, Y., Tian, J., Li, S., He, D., Li, A., Tian, B., Mao, L., Gao, H., et al. (2021) · Journal of Translational Medicine · doi:10.1186/s12967-021-02972-6 · Cited by 16
Undifferentiated carcinoma with osteoclast-like giant cells of the pancreas harboring KRAS and BRCA mutations: case report and whole exome sequencing analysis
Yang, G., Yin, J., Ou, K., Du, Q., Ren, W., Jin, Y., Peng, L., & Yang, L. (2020) · BMC Gastroenterology · doi:10.1186/s12876-020-01351-7 · Cited by 15
Intraparenchymal metastases as a cause for local recurrence of pancreatic cancer
Kiemen, A. L., Choi, Y. G., Braxton, A. M., Almagro-Pérez, C., Graham, S., Grahn, M. P., Nanda, N., Roberts, N. J., Wood, L. D., Wu, P., et al. (2022) · Histopathology · doi:10.1111/his.14839 · Cited by 15
Self-citation
The Clinical Utility of Biomarkers in the Management of Pancreatic Adenocarcinoma
Jazieh, K., Foote, M. B., & Diaz, L. A. (2014) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2013.11.007 · Cited by 16
EBV-associated lymphoepithelioma-like carcinoma of the pancreas: Case report with targeted sequencing analysis
Samdani, R. T., Hechtman, J. F., O'Reilly, E. M., DeMatteo, R. P., & Sigel, C. (2015) · Pancreatology · doi:10.1016/j.pan.2015.03.016 · Cited by 15
Models of pancreatic ductal adenocarcinoma
Dennaoui, R., Shrestha, H., & Wagner, K. (2021) · Cancer and Metastasis Reviews · doi:10.1007/s10555-021-09989-9 · Cited by 19
Hepatic myofibroblasts exert immunosuppressive effects independent of the immune checkpoint regulator PD-L1 in liver metastasis of pancreatic ductal adenocarcinoma
Beckinger, S., Daunke, T., Aldag, L., Krüger, S., Heckl, S. M., Wesch, D., Schäfer, H., Röcken, C., Rahn, S., & Sebens, S. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1160824 · Cited by 14
Therapeutic Approaches for Metastatic Pancreatic Adenocarcinoma
Rubinson, D. A., & Wolpin, B. M. (2015) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2015.04.012 · Cited by 14
Bioinformatic analysis reveals pancreatic cancer molecular subtypes specific to the tumor and the microenvironment
Large, T. Y. S. L., Prado, M. M., Krell, J., Bijlsma, M. F., Meijer, L. L., Geert Kazemier, M., Frampton, A. E., & Giovannetti, E. (2016) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2016.1175940 · Cited by 14
Next generation sequencing of pancreatic ductal adenocarcinoma: right or wrong?
Connor, A. A., & Gallinger, S. (2017) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2017.1324296 · Cited by 14
Non-canonical ALK7 pathways promote pancreatic cancer metastasis through β-catenin/MMP-mediated basement membrane breakdown and intravasation
Kolarzyk, A. M., Kwon, Y., Oh, E., Lee, K.-J., Cho, S.-Y., Cano, I., Lu, R., Kwak, T., Lee, J., Wong, G., et al. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02384-w · Cited by 13
Comparative mutational landscape analysis of patient-derived tumour xenografts
Brait, M., Izumchenko, E., Kagohara, L. T., Long, S., Wysocki, P., Faherty, B., Fertig, E. J., Khor, T. O., Bruckheimer, E. M., Baía, G. S., et al. (2017) · British Journal of Cancer · doi:10.1038/bjc.2016.450 · Cited by 14
Pharmacologic Targeting of TFIIH Suppresses KRAS-Mutant Pancreatic Ductal Adenocarcinoma and Synergizes with TRAIL
Moser, R. D., Annis, J. E., Nikolova, O. H., Whatcott, C., Gurley, K. E., Méndez, E., Moran‐Jones, K., Dorrell, C., Sears, R. C., Kuo, C. J., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-4222 · Cited by 12
Expanding the ubiquitin code in pancreatic cancer
Yang, W., Wang, S., Tong, S., Zhang, W., & Qin, J. (2023) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2023.166884 · Cited by 11
Therapeutic Strategies for Pancreatic-Cancer-Related Type 2 Diabetes Centered around Natural Products
Park, M. N. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242115906 · Cited by 13
Analysis of somatic mutations identifies signs of selection during in vitro aging of primary dermal fibroblasts
Narisu, N., Rothwell, R., Vrtačnik, P., Rodríguez, S., Didion, J. P., Zöllner, S. K., Erdos, M. R., Collins, F. S., & Eriksson, M. (2019) · Aging Cell · doi:10.1111/acel.13010 · Cited by 11
Molecular characteristics of early‐onset pancreatic ductal adenocarcinoma
Debernardi, S., Liszka, Ł., Ntala, C., Steiger, K., Esposito, I., Carlotti, E., Baker, A., McDonald, S. A. C., Graham, T. A., Dmitrović, B., et al. (2023) · Molecular Oncology · doi:10.1002/1878-0261.13576 · Cited by 11
Pancreatic cancer cell- and cancer-associated fibroblast-derived exosomes in disease progression, metastasis, and therapy
Chen, Y., Kleeff, J. H., & Sunami, Y. (2024) · Discover Oncology · doi:10.1007/s12672-024-01111-z · Cited by 11
Reprogramming tumor-associated macrophages with lipid nanosystems reduces PDAC tumor burden and liver metastasis
Palencia‐Campos, A., Ruíz-Cañas, L., Abal-Sanisidro, M., López-Gil, J. C., Batres-Ramos, S., Saraiva, S. M., Yagüe, B., Navarro, D., Alcalá, S., Rubiolo, J. A., et al. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-03010-5 · Cited by 11
Genomic alterations drive metastases formation in pancreatic ductal adenocarcinoma cancer: deciphering the role of CDKN2A and CDKN2B in mediating liver tropism
Journo, S., Goldberg, A. K., Sokol, E. S., Zinger, L., Pasmanik, M., Sarvin, B. A., Simkin, D., Fuchs, S., Shlomi, T., Wolf, I., et al. (2022) · Oncogene · doi:10.1038/s41388-022-02184-2 · Cited by 11
Molecular and Genetic Basis of Pancreatic Carcinogenesis
Bernard, V., Fleming, J. B., & Maitra, A. (2016) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2015.11.003 · Cited by 13
Gastrointestinal cancer: molecular pathogenesis and targeted therapy
Jin, Y., He, X., & Wu, Y. (2025) · Molecular Biomedicine · doi:10.1186/s43556-025-00361-9 · Cited by 13
Development and evaluation of cancer differentiation analysis technology: a novel biophysics-based cancer screening method
Xie, L., Du, X., Wang, S., Shi, P., Qian, Y., Zhang, W., Tang, X., Lin, Y., Chen, J., Peng, L., et al. (2021) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2021.2013201 · Cited by 10
Plasticity and Tumor Microenvironment in Pancreatic Cancer: Genetic, Metabolic, and Immune Perspectives
Hashimoto, A., & Hashimoto, S. (2024) · Cancers · doi:10.3390/cancers16234094 · Cited by 11
Prognostic significance of p16 protein in pancreatic ductal adenocarcinoma
Iwatate, Y., Hoshino, I., Ishige, F., Itami, M., Chiba, S., Arimitsu, H., Yanagibashi, H., Nagase, H., Yokota, H., & Takayama, W. (2020) · Molecular and Clinical Oncology · doi:10.3892/mco.2020.2047 · Cited by 10
Impact of completeness of adjuvant gemcitabine, relapse pattern, and subsequent therapy on outcome of patients with resected pancreatic ductal adenocarcinoma – A pooled analysis of CONKO-001, CONKO-005, and CONKO-006 trials
Kurreck, A., Weckwerth, J., Modest, D. P., Striefler, J. K., Bahra, M., Bischoff, S., Pelzer, U., Oettle, H., Krüger, S., Riess, H. B., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.03.036 · Cited by 10
Optimal value of CA19-9 determined by KRAS-mutated circulating tumor DNA contributes to the prediction of prognosis in pancreatic cancer patients
Watanabe, F., Suzuki, K., Tamaki, S., Abe, I., Endo, Y., Takayama, Y., Ishikawa, H., Kakizawa, N., Saito, M., Futsuhara, K., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-00060-9 · Cited by 10
En marche vers une oncologie personnalisée : l’apport des techniques génomiques et de l’intelligence artificielle dans l’usage des biomarqueurs tumoraux circulants
Perrier, A., Hainaut, P. L., Guenoun, A., Nguyen, D.-P., Lamy, P., Guerber, F., Troalen, F., Denis, J. A., & Boissan, M. (2022) · Bulletin du Cancer · doi:10.1016/j.bulcan.2021.12.005 · Cited by 10
Genetic Alterations Predict Long-Term Survival in Ductal Adenocarcinoma of the Pancreatic Head
Safi, S. A., Häberle, L., Goering, W., Keitel, V., Fluegen, G., Stoecklein, N. H., Rehders, A., Knoefel, W. T., & Esposito, I. (2022) · Cancers · doi:10.3390/cancers14030850 · Cited by 10
Predictors of Long-Term Survival in Pancreatic Ductal Adenocarcinoma after Pancreatectomy: TP53 and SMAD4 Mutation Scoring in Combination with CA19-9
Ono, M., Ono, Y., Nakamura, T., Tsuchikawa, T., Kuraya, T., Kuwabara, S., Nakanishi, Y., Asano, T., Matsui, A., Tanaka, K., et al. (2022) · Annals of Surgical Oncology · doi:10.1245/s10434-022-11630-0 · Cited by 10
Preoperative Serum Thymidine Kinase Activity as Novel Monitoring, Prognostic, and Predictive Biomarker in Pancreatic Cancer
Felix, K., Hinz, U., Dobiasch, S., Hackert, T., Bergmann, F., Neumüller, M., Gronowitz, S., Bergqvist, M., & Strobel, O. (2017) · Pancreas · doi:10.1097/mpa.0000000000000966 · Cited by 10
Circulating Cell-Free Nucleic Acids as Biomarkers for Diagnosis and Prognosis of Pancreatic Cancer
Marin, A. M., Sanchuki, H. B. S., Namur, G. N., Uno, M., Zanette, D. L., & Aoki, M. N. (2023) · Biomedicines · doi:10.3390/biomedicines11041069 · Cited by 9
The Landscape of Genetic Alterations Stratified Prognosis in Oriental Pancreatic Cancer Patients
Guo, S., Shi, X., Gao, S., Hou, Q., Jiang, L., Li, B., Shen, J., Wang, H., Shen, S., Zhang, G., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.717989 · Cited by 9
Genetic landscape of pancreatic cancer: a narrative review
Yakar, D. O., Bozkirli, B. O., & Ceyhan, G. O. (2022) · Chinese Clinical Oncology · doi:10.21037/cco-22-4 · Cited by 11
Molecular Landscape and Prognostic Biomarker Analysis of Advanced Pancreatic Cancer and Predictors of Treatment Efficacy of AG Chemotherapy
Du, J., Qiu, X., Lu, C., Zhu, Y., Kong, W., Xu, M., Zhang, X., Tang, M., Chen, J., Li, Q., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.844527 · Cited by 10
The Mutational Status of Driver Genes in Patients With Resected Pancreatic Ductal Adenocarcinoma Is Associated With Pathological Characteristics and Overall Survival
Campbell, B. A., Solinas, D., Blackford, A. L., Molin, M. D., Purchla, J., McPhaul, T. J., Chidambaram, S., Cameron, J. L., Lin, M., Hruban, R. H., et al. (2025) · Annals of Surgery · doi:10.1097/sla.0000000000006794 · Cited by 8
Self-citation
Transcriptomic Plasticity Is a Hallmark of Metastatic Pancreatic Cancer
Jiménez-Sánchez, A., Persad, S., Hayashi, A., Umeda, S., Sharma, R., Xie, Y., Mehta, A., Park, W., Masilionis, I., Chu, T., et al. (2025) · Cancer Research · doi:10.1158/0008-5472.can-25-1117 · Cited by 9
Self-citation
Epigenetic markers and therapeutic targets for metastasis
Kravitz, C. J., Yan, Q., & Nguyen, D. X. (2023) · Cancer and Metastasis Reviews · doi:10.1007/s10555-023-10109-y · Cited by 9
Synthesis and biological activity of 11-Oxygenated and heterocyclic estrone analogs in pancreatic cancer monolayers and 3D spheroids
Alseud, K., Ostlund, T., Durymanov, M. O., Reineke, J., & Halaweish, F. T. (2024) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2024.117678 · Cited by 8
Pancreatic Cancer
Herman, J. M., Crane, C. H., Iacobuzio–Donahue, C. A., & Abrams, R. A. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-24098-7.00048-4 · Cited by 8
Self-citation
Individualized prognostic signature for pancreatic carcinoma validated by integrating immune-related gene pairs (IRGPs)
Li, Y., Yao, P., Zhao, K., Ye, Z., Zhang, H., Cao, J., Zhang, S., & Xing, C. (2021) · Bioengineered · doi:10.1080/21655979.2020.1860493 · Cited by 8
Intact SMAD-4 is a predictor of increased locoregional recurrence in upfront resected pancreas cancer receiving adjuvant therapy
Gits, H. C., Tang, A., Harmsen, W. S., Bamlet, W. R., Graham, R. P., Petersen, G. M., Smyrk, T. C., Mahipal, A., Kowalchuk, R. O., Ashman, J. B., et al. (2021) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo-21-55 · Cited by 7
P53 immunolabeling in EUS‐FNA biopsy can predict low resection rate and early recurrence in resectable or borderline resectable pancreatic cancer treated with neoadjuvant therapy
Oshima, M., Okano, K., Kamada, H., Suto, H., Ando, Y., Ibuki, E., Ishikawa, R., Masaki, T., Haba, R., & Suzuki, Y. (2022) · Journal of Hepato-Biliary-Pancreatic Sciences · doi:10.1002/jhbp.1286 · Cited by 8
Matrix stiffness regulates the protein profile of extracellular vesicles of pancreatic cancer cell lines
Ferrara, B., Bourgoin‐Voillard, S., Habert, D., Vallée, B., Nicolás‐Boluda, A., Simanic, I., Seve, M., Vingert, B., Gazeau, F., Castellano, F., et al. (2024) · PROTEOMICS · doi:10.1002/pmic.202400058 · Cited by 8
Real-World Validation of the Purity Independent Subtyping of Tumors Classifier for Informing Therapy Selection in Pancreatic Ductal Adenocarcinoma
Wenric, S., Sangli, C., Guittar, J. L., Islam, F., Zander, A. D., Hyun, S. W., Davison, J. M., Mayhew, G. M., Beebe, K. D., Beauchamp, K. A., et al. (2025) · JCO Precision Oncology · doi:10.1200/po-25-00197 · Cited by 7
Tumor microenvironment subtyping in pancreatic ductal adenocarcinoma: New avenues for personalized therapeutic strategies
Srinivasan, D., Gout, J., Kleger, A., & Roger, É. (2025) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2025.115697 · Cited by 7
Can physician gestalt predict survival in patients with resectable pancreatic adenocarcinoma?
Pak, L. M., Gönen, M., Seier, K. P., Balachandran, V. P., D'Angelica, M. I., Jarnagin, W. R., Kingham, T. P., Allen, P. J., Gian, R. K., & Simpson, A. L. (2017) · Abdominal Radiology · doi:10.1007/s00261-017-1407-x · Cited by 7
Safety assessment of metarrestin in dogs: A clinical candidate targeting a subnuclear structure unique to metastatic cancer cells
Bourdi, M., Rudloff, U., Patnaik, S., Marugán, J., & Terse, P. (2020) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2020.104716 · Cited by 7
Sites of Distant Metastases and Cancer-Specific Survival in Intraductal Papillary Mucinous Neoplasm With Associated Invasive Carcinoma: A Study of 1,178 Patients
Huang, X., You, S., Ding, G., Liu, X., Wang, J., Gao, Y., & Zheng, J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.681961 · Cited by 7
Identification of the Immune Cell Infiltration Landscape in Pancreatic Cancer to Assist Immunotherapy
Wang, Z., Zou, W., Wang, F., Zhang, G., Chen, K., Hu, M., & Liu, R. (2021) · Future Oncology · doi:10.2217/fon-2021-0495 · Cited by 7
Quantitative Analysis of TP53-Related Lung Cancer Based on Radiomics
Qiao, H., Ding, Z., Zhu, Y., Wei, Y., Xiao, B., Zhao, Y., & Feng, Q. (2022) · International Journal of General Medicine · doi:10.2147/ijgm.s392404 · Cited by 7
Examination of Wnt signaling as a therapeutic target for pancreatic ductal adenocarcinoma (PDAC) using a pancreatic tumor organoid library (PTOL)
Hawkins, H. J., Yacob, B. W., Brown, M. E., Goldstein, B. R., Arcaroli, J. J., Bagby, S. M., Hartman, S. J., MacBeth, M. L., Goodspeed, A. E., Danhorn, T., et al. (2024) · PLoS ONE · doi:10.1371/journal.pone.0298808 · Cited by 7
Biology, pathophysiology, and epidemiology of pancreatic cancer
Dariya, B., Alam, A., & Nagaraju, G. P. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-819457-7.00001-3 · Cited by 7
STRAP as a New Therapeutic Target for Poor Prognosis of Pancreatic Ductal Adenocarcinoma Patients Mainly Caused by TP53 Mutation
Hu, S., Chen, X., Xu, X., Zheng, C., Huang, W., Zhou, Y., Akuetteh, P. D. P., Yang, H., Shi, K., Chen, B., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.594224 · Cited by 7
Genetic landscape of pancreatic adenocarcinoma patients: a pilot study from Pakistan
Ali, S. M., Adnan, Y., Ahmad, Z., Farooqui, H. A., Chawla, T. U., & Ali, S. M. A. (2021) · Molecular Biology Reports · doi:10.1007/s11033-021-06964-z · Cited by 6
Genomic evolution of pancreatic cancer at single-cell resolution
Zhang, H., Sashittal, P., Karnoub, E.-R. R., Jakatdar, A., Umeda, S., Hong, J., Noronha, A. M., Cardenas, A., Erakky, A., McIntyre, C. A., et al. (2026) · Nature Genetics · doi:10.1038/s41588-025-02468-9 · Cited by 5
Self-citation
Unraveling pancreatic ductal adenocarcinoma at single-cell resolution with spatial insights: From mechanisms to clinical translation
Qi, H., Lv, G., Zhang, S., Xue, R., & Liu, M. (2026) · Cancer Letters · doi:10.1016/j.canlet.2026.218391 · Cited by 8
Evaluation of Occult Liver Metastases in Pancreatic Adenocarcinoma by Diffusion‐Weighted Related Magnetic Resonance Imaging
Wang, F., Xu, X., Chen, Y., Xu, J., Ji, W., & Yu, D. (2025) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.29747 · Cited by 5
Targeted nanostrategies eliminate pre-metastatic niche of cancer
Wang, J., Zhang, N., Ding, X., Fu, C., Li, X., Li, B., Ding, J., & Sun, T. (2024) · Nano Research · doi:10.1007/s12274-024-6412-0 · Cited by 5
Current Advances in the Use of Tissue Engineering for Cancer Metastasis Therapeutics
Katti, P. D., & Jasuja, H. (2024) · Polymers · doi:10.3390/polym16050617 · Cited by 5
Clinical Outcome of Resected Remnant Pancreatic Cancer After Resection of the Primary Pancreatic Cancer
Suzuki, S., Shimoda, M., Shimazaki, J., Maruyama, T., & Nishida, K. (2018) · Journal of Investigative Surgery · doi:10.1080/08941939.2018.1452995 · Cited by 5
Molecular Profiling in Pancreatic Cancer: Current Role and Its Impact on Primary Surgery
Reyes, C. M., Doğruöz, A., Istvánffy, R., Frieß, H., Ceyhan, G. O., & Demir, İ. E. (2021) · Visceral Medicine · doi:10.1159/000519755 · Cited by 5
The multifaceted roles of deubiquitinating enzymes (DUBs) in pancreatic ductal adenocarcinoma
Zhou, M., Wei, R., Zhang, J., Xiong, G., Gong, J., Qin, R., & Wang, M. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-08052-7 · Cited by 4
Durable effect of imatinib and metronomic chemotherapy with capecitabine in pancreatic carcinoma
Al‐Sukhun, S., & Khalidi, K. (2023) · ecancermedicalscience · doi:10.3332/ecancer.2023.1535 · Cited by 4
Microbiome and MicroRNA or Long Non-Coding RNA—Two Modern Approaches to Understanding Pancreatic Ductal Adenocarcinoma
Izdebska, W. M., Daniluk, J., & Nikliński, J. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12175643 · Cited by 4
Combined tumor epithelial and stromal histopathology with keratin 81 expression predicts prognosis for pancreatic ductal adenocarcinoma
Park, E., Yoo, J. E., Hwang, H. K., Kang, C. M., Lee, C., Kim, M. H., Bang, S., & Park, Y. N. (2021) · Journal of Hepato-Biliary-Pancreatic Sciences · doi:10.1002/jhbp.1025 · Cited by 4
Altered Interphase Fluorescence in Situ Hybridization Profiles of Chromosomes 4, 8q24, and 9q34 in Pancreatic Ductal Adenocarcinoma Are Associated with a Poorer Patient Outcome
Gutiérrez, M. L., Muñoz‐Bellvís, L., Sarasquete, M. E., Hernández, D. G., Abad, M., Bengoechea, Ó., Corchete, L. A., González‐González, M., García-García, J., González, M., et al. (2014) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2014.06.007 · Cited by 4

Authors: Yachida, S., White, C. M., Naito, Y., Zhong, Y., Brosnan, J. A., Macgregor-Das, A. M., Morgan, R. A., Saunders, T., Laheru, D. A., Herman, J. M., Hruban, R. H., Klein, A. P., Jones, S., Velculescu, V., Wolfgang, C. L., & Iacobuzio-Donahue, C. A.
Affiliations: Kurume University (JP)
Authors' Affiliations: Departments of 1Pathology, 2Oncology, 3Surgery, and 4Radiation Oncology, The Sol Goldman Pancreatic Cancer Research Center, 5The Lugwig Center for Cancer Genetics and Therapeutics, Johns Hopkins Medical Institutions, Baltimore, Maryland; 6National Cancer Center Research Institute, Tokyo; and 7Kurume University School of Medicine, Kurume, Fukuoka, Japan
ORCID: Yachida, Shinichi
Naito, Yoshiki
Zhong, Yi
Laheru, Daniel A.
Herman, Joseph M.
Hruban, Ralph H.
Klein, Alison P.
Jones, Siân
Velculescu, Victor
Wolfgang, Christopher L.
Venue: Clinical Cancer Research
Publisher: American Association for Cancer Research (AACR)
Published: 2012-11-14
Volume: 18
Issue: 22
Pages: 6339-6347
ISSN: 1078-0432 (ISSN-L)
1557-3265
DOI: 10.1158/1078-0432.ccr-12-1215
PMC: PMC3500447
OpenAlex: W2155563954
Cited by: 280
References: 43
Citations by year: 2026: 16 · 2025: 18 · 2024: 17 · 2023: 22 · 2022: 27 · 2021: 33 · 2020: 25 · 2019: 15 · 2018: 20 · 2017: 23 · 2016: 15 · 2015: 22 · 2014: 15 · 2013: 12
FWCI: 7.76
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Clinical Cancer Research (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: National Institutes of Health (5r01ca121113-15)
Japan Society for the Promotion of Science (23390326, 24659612)
National Cancer Institute (CA-101955, P20CA101955, R01CA140599, P50CA101955, R01-CA121113, CA-121113, CA140599, P50CA062924, CA 62924)
Topics: Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
Keywords: pancreatic cancer, driver gene alterations, KRAS, CDKN2A, TP53, SMAD4, long-term survival, disease-free survival, metastatic burden, prognostic factors, autopsy tissue
MeSH terms: Aged, DNA Mutational Analysis, Female, Humans, Male, Middle Aged, Pancreatic Neoplasms, Proto-Oncogene Proteins, Risk Factors, Proportional Hazards Models, Tumor Suppressor Protein p53, Proto-Oncogene Proteins p21(ras), Survivors, Disease-Free Survival, ras Proteins, Cyclin-Dependent Kinase Inhibitor p16, Carcinoma, Pancreatic Ductal, Tumor Burden, Smad4 Protein, Kaplan-Meier Estimate

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Clinical Significance of the Genetic Landscape of Pancreatic Cancer and Implications for Identification of Potential Long-term Survivors

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks